{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:52:55Z","timestamp":1791276775372,"version":"4.1.0"},"reference-count":83,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome defined by shared manifestations but produced by diverse combinations of cardiometabolic, vascular, inflammatory, renal, pulmonary, atrial, skeletal-muscle, and aging-related mechanisms. This heterogeneity limits the value of classifications based only on left ventricular ejection fraction and helps explain why many mechanistically plausible interventions have produced neutral average results. Deep phenotyping can move the field from descriptive heterogeneity toward biologically coherent and clinically actionable subtypes by integrating clinical trajectories, advanced imaging, exercise and invasive hemodynamics, circulating biomarkers, multiomics, and digital physiology. Artificial intelligence (AI) offers methods to combine these high-dimensional data, but statistical clusters should not be equated with disease endotypes. A useful subtype must be reproducible across cohorts, anchored to plausible biology, associated with a distinct clinical course, and able to improve diagnosis, therapeutic selection, or clinical-trial design. This Review examines the translational continuum from experimental HFpEF models to human patient subtypes, summarizes the main deep-phenotyping domains and AI approaches, and proposes seven clinically interpretable subtype families: cardiometabolic-inflammatory, hypertensive-vascular aging, atrial myopathy, pulmonary vascular-right ventricular, cardiorenal-congestive, peripheral-frailty, and specific etiologic phenocopies. Current evidence supports a layered treatment strategy in which broadly effective therapies, particularly sodium-glucose cotransporter 2 inhibitors, are combined with phenotype-directed management of obesity, diabetes, mineralocorticoid receptor activation, atrial fibrillation, congestion, pulmonary vascular disease, and physical deconditioning. The central next step is prospective validation of dynamic subtype assignments in external populations and phenotype-enriched trials. Phenogroup labels should therefore be regarded as pragmatic, transitional proxies for dominant mechanisms when those mechanisms cannot yet be measured directly at the individual-patient level; their value lies in improving decisions while the field moves toward fully individualized mechanism-based treatment. Deep phenotyping will be clinically valuable only when it changes a decision and improves an outcome, rather than merely increasing descriptive complexity.<\/jats:p>","DOI":"10.3389\/fcvm.2026.1956165","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:24:54Z","timestamp":1791275094000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Artificial intelligence-enabled deep clinical phenotyping in heart failure with preserved ejection fraction: from patient subtypes to precision care"],"prefix":"10.3389","volume":"13","author":[{"given":"Francisco","family":"Epelde","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Parc Taul\u00ed Hospital Universitari","place":["Sabadell, Spain"]},{"name":"Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA)","place":["Sabadell, Spain"]},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41572-024-00540-y","article-title":"Heart failure with preserved ejection fraction","volume":"10","author":"Hamo","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1056\/NEJMcp2305181","article-title":"Heart failure with preserved ejection fraction","volume":"392","author":"Cannata","year":"2025","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.cardfail.2021.01.022","article-title":"Universal definition and classification of heart failure","volume":"27","author":"Bozkurt","year":"2021","journal-title":"J Card Fail"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.3390\/jcm14144820","article-title":"Heterogeneity in heart failure with preserved ejection fraction: a systematic review of phenotypic classifications and clinical implications","volume":"14","author":"Epelde","year":"2025","journal-title":"J Clin Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","article-title":"A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction","volume":"138","author":"Reddy","year":"2018","journal-title":"Circulation"},{"key":"B9","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/ejhf.2894","article-title":"Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making","volume":"25","author":"Anker","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"B10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","article-title":"Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap","volume":"134","author":"Shah","year":"2016","journal-title":"Circulation"},{"key":"B11","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/heartjnl-2023-323049","article-title":"Rationale and design of the United Kingdom heart failure with preserved ejection fraction registry","volume":"110","year":"2024","journal-title":"Heart"},{"key":"B12","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1161\/CIRCULATIONAHA.116.024822","article-title":"Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction","volume":"135","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.jchf.2018.03.003","article-title":"Hemodynamic correlates and diagnostic role of cardiopulmonary exercise testing in heart failure with preserved ejection fraction","volume":"6","author":"Reddy","year":"2018","journal-title":"JACC Heart Fail"},{"key":"B14","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1161\/CIRCULATIONAHA.115.015884","article-title":"Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone","volume":"132","author":"Shah","year":"2015","journal-title":"Circulation"},{"key":"B15","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.echo.2024.11.008","article-title":"Exercise-induced reduction in left ventricular ejection fraction in the absence of coronary artery disease: clinical characteristics and outcomes","volume":"38","author":"Fazzini","year":"2025","journal-title":"J Am Soc Echocardiogr"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1093\/cvr\/cvac133","article-title":"Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions","volume":"118","author":"Pugliese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1002\/ejhf.2741","article-title":"Connecting epicardial adipose tissue and heart failure with preserved ejection fraction: mechanisms, management and modern perspectives","volume":"24","author":"Van Woerden","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e327433","DOI":"10.1161\/CIRCRESAHA.125.327433","article-title":"Single-cell analysis of human heart failure with preserved ejection fraction","volume":"139","author":"Hahn","year":"2026","journal-title":"Circ Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1038\/s42003-025-08827-w","article-title":"Single-cell transcriptomic profiling reveals cell type heterogeneity between HFpEF and HFrEF","volume":"8","author":"Xiao","year":"2025","journal-title":"Commun Biol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.1093\/eurheartj\/ehab389","article-title":"Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models","volume":"42","author":"Withaar","year":"2021","journal-title":"Eur Heart J"},{"key":"B21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41586-019-1100-z","article-title":"Nitrosative stress drives heart failure with preserved ejection fraction","volume":"568","author":"Schiattarella","year":"2019","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1093\/cvr\/cvaa256","article-title":"The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction","volume":"117","author":"Withaar","year":"2021","journal-title":"Cardiovasc Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00395-024-01074-w","article-title":"Single-cell transcriptomics reveal distinctive patterns of fibroblast activation in heart failure with preserved ejection fraction","volume":"119","author":"Lanzer","year":"2024","journal-title":"Basic Res Cardiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41586-024-08008-5","article-title":"Targeting immune-fibroblast cell communication in heart failure","volume":"635","author":"Amrute","year":"2024","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","first-page":"677727","DOI":"10.3389\/fcvm.2021.677727","article-title":"A porcine model of heart failure with preserved ejection fraction induced by chronic pressure overload characterized by cardiac fibrosis and remodeling","volume":"8","author":"Tan","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2310085","DOI":"10.1002\/adfm.202310085","article-title":"Modulating cardiac hemodynamics using tunable soft robotic sleeves in a porcine model of HFpEF physiology for device testing applications","volume":"34","author":"Rosalia","year":"2024","journal-title":"Adv Funct Mater"},{"key":"B28","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00395-025-01112-1","article-title":"A new model of heart failure with preserved ejection fraction induced by metabolic syndrome in ossabaw miniature swine","volume":"120","author":"Tang","year":"2025","journal-title":"Basic Res Cardiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1099453","DOI":"10.3389\/fcvm.2023.1099453","article-title":"Evaluation of large animal models for preclinical studies of heart failure with preserved ejection fraction using clinical score systems","volume":"10","author":"Li","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1161\/CIRCULATIONAHA.114.010637","article-title":"Phenomapping for novel classification of heart failure with preserved ejection fraction","volume":"131","author":"Shah","year":"2015","journal-title":"Circulation"},{"key":"B31","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/ejhf.1621","article-title":"Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis","volume":"22","author":"Segar","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B32","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jchf.2019.09.009","article-title":"Clinical phenogroups in heart failure with preserved ejection fraction: detailed phenotypes, prognosis, and response to spironolactone","volume":"8","author":"Cohen","year":"2020","journal-title":"JACC Heart Fail"},{"key":"B33","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1136\/heartjnl-2019-315481","article-title":"Identification of novel pheno- groups in heart failure with preserved ejection fraction using machine learning","volume":"106","author":"Hedman","year":"2020","journal-title":"Heart"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.3390\/medicina61111937","article-title":"Machine-learning-driven phenotyping in heart failure with preserved ejection fraction: current approaches and future directions","volume":"61","author":"Potoupni","year":"2025","journal-title":"Medicina (B Aires)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jjcc.2025.08.018","article-title":"Artificial intelligence in HFpEF: diagnosis, prognosis, and management strategies","volume":"87","author":"Yi","year":"2026","journal-title":"J Cardiol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1002\/ehf2.14913","article-title":"Long-term outcomes of phenoclusters in preclinical heart failure with preserved and mildly reduced ejection fraction","volume":"11","author":"Fazzini","year":"2024","journal-title":"ESC Heart Fail"},{"key":"B37","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1002\/ejhf.2169","article-title":"Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction","volume":"23","author":"Uijl","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"B38","doi-asserted-by":"publisher","first-page":"xuag037","DOI":"10.1093\/ejhf\/xuag037","article-title":"Outcome trajectories in hospitalized heart failure with preserved ejection fraction: a machine learning cluster analysis","volume":"10","author":"Spagnolin","year":"2026","journal-title":"Eur J Heart Fail"},{"key":"B39","doi-asserted-by":"publisher","first-page":"100452","DOI":"10.1016\/j.jacadv.2023.100452","article-title":"Automated echocardiographic detection of heart failure with preserved ejection fraction using artificial intelligence","volume":"2","author":"Akerman","year":"2023","journal-title":"JACC Adv"},{"key":"B40","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.echo.2024.06.016","article-title":"Automated echocardiographic detection of heart failure with preserved ejection fraction using artificial intelligence is associated with cardiac mortality and heart failure hospitalization","volume":"37","author":"Cassianni","year":"2024","journal-title":"J Am Soc Echocardiogr"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e078378","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD\u2009+\u2009AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"Br Med J"},{"key":"B42","doi-asserted-by":"publisher","first-page":"103462","DOI":"10.1016\/j.eclinm.2025.103462","article-title":"Machine learning-based phenotyping and assessment of treatment responses in heart failure with preserved ejection fraction","volume":"88","author":"Li","year":"2025","journal-title":"eClinicalMed"},{"key":"B43","doi-asserted-by":"publisher","first-page":"i115","DOI":"10.1093\/eurheartjsupp\/suae095","article-title":"Towards a phenotype profiling of the patients with heart failure and preserved ejection fraction","volume":"27","author":"Bonfioli","year":"2025","journal-title":"Eur Heart J Suppl"},{"key":"B44","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"B45","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12933-025-02774-w","article-title":"Cardiometabolic heart failure with preserved ejection fraction: from molecular signatures to personalized treatment","volume":"24","author":"Gorica","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"B47","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s10741-024-10450-6","article-title":"GLP-1 receptor agonists as promising anti-inflammatory agents in heart failure with preserved ejection fraction","volume":"30","author":"Bonfioli","year":"2025","journal-title":"Heart Fail Rev"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1002\/ehf2.14422","article-title":"Rising arterial stiffness with accumulating comorbidities associates with heart failure with preserved ejection fraction","volume":"10","author":"Ali","year":"2023","journal-title":"ESC Heart Fail"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1253\/circj.CJ-21-0795","article-title":"Left atrial myopathy in heart failure with preserved ejection fraction","volume":"87","author":"Omote","year":"2023","journal-title":"Circ J"},{"key":"B51","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"B52","doi-asserted-by":"publisher","first-page":"euae204","DOI":"10.1093\/europace\/euae204","article-title":"Atrial cardiomyopathy revisited-evolution of a concept: a clinical consensus statement","volume":"26","author":"Goette","year":"2024","journal-title":"Europace"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1002\/ejhf.3782","article-title":"Atrial cardiomyopathy: from healthy atria to atrial failure. A clinical consensus statement of the heart failure association of the ESC","volume":"27","author":"Weerts","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.jchf.2023.03.003","article-title":"Shedding light on latent pulmonary vascular disease in heart failure with preserved ejection fraction","volume":"11","author":"Caravita","year":"2023","journal-title":"JACC Heart Fail"},{"key":"B55","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1002\/ejhf.2867","article-title":"Biventricular cardiac power reserve in heart failure with preserved ejection fraction","volume":"25","author":"Alogna","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"B56","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1093\/eurheartj\/ehz713","article-title":"The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction","volume":"40","author":"Reddy","year":"2019","journal-title":"Eur Heart J"},{"key":"B57","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1001\/jama.2015.17346","article-title":"Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction","volume":"315","author":"Kitzman","year":"2016","journal-title":"JAMA"},{"key":"B58","doi-asserted-by":"publisher","first-page":"oeae033","DOI":"10.1093\/ehjopen\/oeae033","article-title":"Exercise training improves exercise capacity and quality of life in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"4","author":"Baral","year":"2024","journal-title":"Eur Heart J Open"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1093\/eurjhf\/hft071","article-title":"Preferences of heart failure patients in daily clinical practice: quality of life or longevity","volume":"15","author":"Kraai","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/eurjpc\/zwad400","article-title":"Quality of life in heart failure. The heart of the matter. A scientific statement of the heart failure association and the European association of preventive cardiology of the ESC","volume":"27","author":"Volterrani","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1002\/ehf2.15205","article-title":"State of precision medicine for heart failure with preserved ejection fraction in a new therapeutic age","volume":"12","author":"Rasalam","year":"2025","journal-title":"ESC Heart Fail"},{"key":"B71","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1002\/ejhf.70041","article-title":"Deep phenotyping of heart failure with preserved ejection fraction through multi-omics integration","volume":"27","author":"Versnjak","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"B72","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.echo.2024.05.003","article-title":"Exercise stress echocardiography- based phenotyping of heart failure with preserved ejection fraction","volume":"37","author":"Saito","year":"2024","journal-title":"J Am Soc Echocardiogr"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1002\/ehf2.15163","article-title":"Invasive haemodynamic assessment in heart failure with preserved ejection fraction","volume":"12","author":"Wattanachayakul","year":"2025","journal-title":"ESC Heart Fail"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e037567","DOI":"10.1161\/JAHA.124.037567","article-title":"Phenotypic trajectories from acute to stable phase in heart failure with preserved ejection fraction: insights from the PURSUIT-HFpEF study","volume":"14","author":"Matsuoka","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e011792","DOI":"10.1161\/CIRCHEARTFAILURE.124.011792","article-title":"Proteomics identify clinical phenotypes and predict functional outcomes in heart failure with preserved ejection fraction: insights from VITALITY-HFpEF","volume":"17","author":"defilippi","year":"2024","journal-title":"Circ Heart Fail"},{"key":"B76","doi-asserted-by":"publisher","first-page":"e033544","DOI":"10.1161\/JAHA.123.033544","article-title":"Aptamer proteomics for biomarker discovery in heart failure with preserved ejection fraction: the PARAGON-HF proteomic substudy","volume":"13","author":"Patel-Murray","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e033410","DOI":"10.1161\/JAHA.123.033410","article-title":"Urinary proteomics and outcomes in heart failure with preserved ejection fraction","volume":"13","author":"Carland","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"B78","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jchf.2024.02.018","article-title":"Targeted metabolomic profiling of dapagliflozin in heart failure with preserved ejection fraction: the PRESERVED-HF trial","volume":"12","author":"Selvaraj","year":"2024","journal-title":"JACC Heart Fail"},{"key":"B79","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1002\/ehf2.15285","article-title":"Plasma metabolomics identifies signatures that distinguish heart failure with reduced and preserved ejection fraction","volume":"12","author":"Naeem","year":"2025","journal-title":"ESC Heart Fail"},{"key":"B80","doi-asserted-by":"publisher","first-page":"101334","DOI":"10.1016\/j.jacbts.2025.101334","article-title":"Integrated systems biology identifies disruptions in mitochondrial function and metabolism as key contributors to HFpEF","volume":"10","author":"Gibb","year":"2025","journal-title":"JACC Basic Transl Sci"},{"key":"B81","doi-asserted-by":"publisher","first-page":"120717","DOI":"10.1016\/j.cca.2025.120717","article-title":"Olink proteomics profiling platform reveals myocardial metabolism-associated protein biomarkers in heart failure with preserved ejection fraction (HFpEF)","volume":"580","author":"Chen","year":"2026","journal-title":"Clin Chim Acta"},{"key":"B82","doi-asserted-by":"publisher","first-page":"e1573403X433317","DOI":"10.2174\/011573403X433317251107113544","article-title":"Heart failure in the era of precision medicine: advances, challenges, and future directions","volume":"22","author":"Epelde","year":"2026","journal-title":"Curr Cardiol Rev"},{"key":"B83","doi-asserted-by":"publisher","first-page":"e1573403X410467","DOI":"10.2174\/011573403X410467251117092411","article-title":"Artificial intelligence: a game changer in the diagnosis, treatment, and management of chronic heart failure","volume":"22","author":"Epelde","year":"2026","journal-title":"Curr Cardiol Rev"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1956165\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:24:55Z","timestamp":1791275095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1956165\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":83,"alternative-id":["10.3389\/fcvm.2026.1956165"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1956165","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"article-number":"1956165"}}